Compare Fluor Corporation Common Stock (FLR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fluor Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Fluor Corporation Common Stock trades at $46.88 (market cap $6.37B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Fluor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluor Corporation Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| FLR | RGEN | |
|---|---|---|
Market Cap | $6.37B | $11.31B |
Volume | 1,709,507 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $57.50 | $194.57 |
52-Week Low | $39.63 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.40B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fluor Corporation (FLR) trades at $49.75, showing minimal daily movement with a 0.08% gain. The stock faces bearish technical signals but maintains analyst support with a $62.33 consensus price target. Recent Q2 2026 earnings beat expectations, though profitability remains challenged with negative margins. The company secured a significant $7.5 billion LNG Canada Phase 2 project, providing substantial future revenue visibility amid ongoing operational restructuring.
FLR presents a turnaround opportunity with strong backlog coverage but carries execution risks. The stock trades at attractive valuation multiples (P/S 0.49) with 53.6% analyst buy ratings, yet negative cash flow and margin pressures require careful monitoring. Near-term performance hinges on successful project execution and margin improvement from the shift to reimbursable contracts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fluor Corporation Common Stock
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
